Indo-Korea trade expansion in mutual interest: Moon Jae

Agencies
July 9, 2018

New Delhi, Jul 9: South Korean President Moon Jae-in today called for expansion of bilateral trade with India, saying it was in the interest of both nations.

Addressing the India-Korea Business Forum here, Moon hoped that upgrade of the Comprehensive Economic Partnership Agreement (CEPA) and Regional Comprehensive Economic Partnership (RCEP) Agreement negotiations can be “concluded as early as possible”.

"India and South Korea are the world's 7th and 11th largest economies.

However, trade between the two countries came to USD 20 billion last year, which is not small but far short of our expectations," Moon said at the forum attended by around 400 top business leaders from both countries.

Commerce and Industry Minister Suresh Prabhu said he has held discussion on the ‘Early Harvest’ under CEPA with his Korean counterpart Kim Hyun-Chong.

Prabhu said the two nations are taking forward the discussion and have decided to take their relationship to the new level.

The two ministers today signed the joint statement on the Early Harvest package in the India-Korea CEPA upgradation, according to an official statement.

Stressing that India and Korea can lead the fourth industrial revolution, Moon said an MoU will be signed tomorrow towards the establishment of a Future Vision Technology Group to boost bilateral cooperation in science and technology.

Referring to the recent rapprochement between his country with North Korea, Moon said business opportunities in his country could rise substantially if “we can establish peace in the Korean Peninsula”.

“South Korea is facing a historic transition. We have opened a way to the establishment of peace through the South-North Korea summit and North Korea-US summit.

“Once peace is established, investment conditions in South Korea will improve and many new business opportunities may be created," the president said.

He shared that bilateral cooperation between India and Korea was being expanded to newer areas like ship building, medical devices and food processing.

Moon pointed out that Korean companies were keen to participate in large-scale infrastructure development in India, especially in the development of Smart Cities.

He said the two nations share many common values while both their governments pushed for what he termed the "3Ps" -- people-oriented peace and prosperity.

"I am committed to raise the relationship with India which is embodied in the New Southern Policy, which is also aligned with Act East Policy pursued by Prime Minister Narendra Modi,"Moon said.

The president said Korea will contribute actively to Make in India initiative of the government, adding that around 500 Korean companies are present in India.

Besides, Prabhu referred to the processing of marine products exported from India as one of the sunrise sectors for future bilateral cooperation, adding that there lies a great opportunity for Korean companies to come and invest in India.

He said India was thinking of setting up a special economic zone which can only house the Korean companies.

“I will urge my Korean friends that this is the place where you should invest because in the next 7-8 years India will be a 5 trillion dollar economy and if you take 15 years from now India will be a 10 trillion dollar economy. So the growth in India is inevitable, we are on course to do that,” Prabhu said.

He outlined manufacturing, services and agriculture as the areas having huge potential to enhance bilateral economic cooperation, adding that he has already discussed this with his Korean counterpart.

“We would like to give a concrete shape to this through the business participation,” he added.

The minister highlighted the importance of the South Korean President’s visit to India at a time when the country was in a growth trajectory, and expressed confidence that his coming here would help India’s economy touch the 8 per cent mark soon from 7.6 per cent in the last quarter.

India and South Korea are working to revise the CEPA which has been in place since 2009.

According to estimates, India’s export to South Korea stood at USD 4.4 billion in 2017-18, with an annual growth of 5.2 per cent. On the other hand, import from Korea was four times larger at USD 16.4 billion and rose 30 per cent in 2017-18.

The Korean President also highlighted India’s contribution to the world through Bollywood, Yoga, Nobel Laureates and meditation, observing that his daughter was a Yoga instructor and movies like Haathi Mere Saathi, Three Idiots and Dangal have garnered huge popularity in Korea.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 13,2020

Visakhapatnam, Jun 13: A four-month-old baby who was on ventilator treatment for 18 days for COVID-19 was on Friday evening discharged from hospital after testing negative.

"A tribal woman of East Godavari named Laxmi was infected with COVID-19 in May, later the doctors confirmed that her four-month-old baby was also infected," said District Collector, Vinay Chand.

"The baby was shifted to Visakhapatnam VIMS hospital on May 25. She was treated for 18 days on a ventilator. Doctors again conducted baby's COVID-19 test recently, following which the reports came negative. After a health check-up, VIMS doctors discharged the baby on Friday evening," he added.

Meanwhile, 14 new COVID-19 positive cases have been reported in Visakhapatnam district on Friday, taking the total number of cases to 252 including one fatality due to the virus.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 25,2020

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 3,2020

New Delhi, Jul 3: In a significant step, ICMR has partnered with Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID Vaccine). It is the first indigenous vaccine being developed by India and is one of the top priority projects which is being monitored at the topmost level of the Government, says ICMR in a statement.

The vaccine is derived from a strain of SARS-CoV-z isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine.

In a letter to the institutes that will be involved in the trails of the vaccine, ICMR has said

"It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials. BBIL is working expeditiously to meet the target. However, final outcome will depend on the cooperation of all clinical trial sites involved in this project. you have been chosen as a clinical trial site of the BBV152 COVID vaccine. ln view of the public health emergency due to COVID-19 pandemic and urgency to launch the vaccine, you are strictly advised to fast track all approvals related to initiation of the clinical trial and ensure that the subject enrollment is initiated no later than 7th July 2020."

The ICMR also asked the institutes to comply with the order, "Kindly note that non-compliance will be viewed very seriously. Therefore, you are advised to treat this project on the highest priority and meet the given timelines without any lapse."

The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.